ChromaDex Corporation

CDXC

US1710774076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
2.95 ^USD	-20.05%		-24.94%	+106.29%

Apr. 09	Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	MT
Mar. 11	HC Wainwright Adjusts Price Target on ChromaDex to $6 From $5, Maintains Buy Rating	MT

ChromaDex Corporation(NasdaqCM:CDXC) dropped from Russell 2000 Growth Index

June 24, 2022 at 12:00 am EDT

Latest news about ChromaDex Corporation

Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	Apr. 09	MT
HC Wainwright Adjusts Price Target on ChromaDex to $6 From $5, Maintains Buy Rating	Mar. 11	MT
Transcript : ChromaDex Corporation, Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q4 Revenue $21.2M, vs. Street Est of $20.7M	Mar. 06	MT
ChromaDex Corporation Provides Earnings Guidance for 2024	Mar. 06	CI
ChromaDex Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
ChromaDex Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
ChromaDex Corporation, Chromadex, Inc. and ChromaDex Analytics, Inc Enter into an Amendment to the Business Financing Agreement Dated November 1, 2019 Among the Borrowers and Western Alliance Bank	Dec. 13	CI
Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+	Dec. 12	CI
ChromaDex Says High-Dose Niagen Safe for Parkinson's Disease Patients in Phase 1 Study	Nov. 30	MT
Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD)	Nov. 30	CI
ChromaDex Reports Positive Data From Phase 2 Study Using Niagen	Nov. 15	MT
Chromadex Corp. Shares Results from Phase II Clinical Study	Nov. 15	CI
Transcript : ChromaDex Corporation, Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (CDXC) CHROMADEX CORPORATION Posts Q3 Revenue $19.5M, vs. Street Est of $20.4M	Nov. 08	MT
ChromaDex Corporation Provides Revenue Guidance for the Year 2023	Nov. 08	CI
ChromaDex Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
ChromaDex Launches New Food Supplement	Nov. 01	MT
ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside)	Nov. 01	CI
ChromaDex Corp. and Zesty Paws Crack the Code on Cellular Health for Dogs With ?Healthy Aging? Line	23-10-26	CI
Chromadex Announces Results from Newly Published Clinical Study, as Reported in the Peer-Reviewed Journal Cell Reports, Demonstrating That Supplementation with Nicotinamide Riboside	23-10-02	CI
ChromaDex Corporation(NasdaqCM:CDXC) dropped from S&P Global BMI Index	23-09-18	CI
Transcript : ChromaDex Corporation, Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q2 Revenue $20.3M, vs. Street Est of $19.5M	23-08-09	MT
ChromaDex Corporation Provides Revenue Guidance for the Year 2023	23-08-09	CI

Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ChromaDex Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.95 USD

Average target price

6.08 USD

Spread / Average Target

+106.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHROMADEX CORPORATION	+106.29%	223M
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+45.15%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research